Timothy Larson MD
Gastrointestinal Cancer, Thoracic Cancer
Medical Director Early Phase Therapeutics Program
Join to View Full Profile
640 Jackson St200Saint Paul, MN 55101
Phone+1 651-254-3321
Dr. Larson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California Davis HealthFellowship, Hematology and Medical Oncology, 1992 - 1995- University of California Davis HealthResidency, Internal Medicine, 1989 - 1992
University of California San Francisco School of MedicineClass of 1989
Certifications & Licensure
CA State Medical License 1990 - Present
MN State Medical License 1995 - 2025
AZ State Medical License 1992 - 2018
FL State Medical License 1991 - 2018
OH State Medical License 2011 - 2018
TX State Medical License 2013 - 2018
WA State Medical License 2008 - 2017
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma Start of enrollment: 2021 May 12
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 4 citationsImlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10 - 20 citationsModified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomize...Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino
Journal for Immunotherapy of Cancer. 2024-03-13 - 13 citationsBrentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.Jonathan W Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt
Blood. 2024-02-29
Abstracts/Posters
- Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and AboveTimothy Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged _60 YearsClinically Relevant AbstractTimothy Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
